Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2011

01-10-2011 | Case Report

A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy

Authors: Nawin Kumar, Prabhat Kumar Sinha, Krishna Pandey, Neena Verma, Chandra Shekhar Lal, Alok Ranjan, Rakesh Bihari Verma, Pradeep Das

Published in: International Journal of Clinical Pharmacy | Issue 5/2011

Login to get access

Abstract

Case We report a 32-year old relapse case of Visceral leishmaniasis, treated with Paromomycin who belonged from a endemic zone of Bihar state, India. After confirmation, he was treated with Amphotericin B, followed by Liposomal Amphotericin B in full course and even in higher dose. But after each therapy, the patient either did not responded or relapsed after treatment. Ultimately, the patient was successfully treated with combination therapy of Liposomal amphotericin B and Miltefosine without any relapse. Conclusion The multi-drug unresponsive Visceral leishmaniasis cases could pose a major threat to treatment strategy in the elimination program. In such situation, combination therapy seems to be a better approach that needs to be explored.
Literature
1.
go back to reference Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, et al. New perspectives on a sub-clinical form of visceral leishmaniasis. J Infect Dis. 1986;154:1003–11.PubMedCrossRef Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, et al. New perspectives on a sub-clinical form of visceral leishmaniasis. J Infect Dis. 1986;154:1003–11.PubMedCrossRef
2.
go back to reference Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India. Clinical Infect Dis. 2000;31(4):1104–7.CrossRef Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India. Clinical Infect Dis. 2000;31(4):1104–7.CrossRef
3.
go back to reference Jha TK, Giri YN, Singh TK, Jha S. Use of amphotericin-B in drug- resistant cases of visceral leishmaniasis in north Bihar, India. Am J Trop Hyg. 1995;52:536–8. Jha TK, Giri YN, Singh TK, Jha S. Use of amphotericin-B in drug- resistant cases of visceral leishmaniasis in north Bihar, India. Am J Trop Hyg. 1995;52:536–8.
4.
go back to reference Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral Leishmaniasis in India. New England J Med. 2007;356(25):2571–81.CrossRef Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral Leishmaniasis in India. New England J Med. 2007;356(25):2571–81.CrossRef
5.
go back to reference Jochim RC, Teixeira C. Leishmania commandeers the host inflammatory response through neutrohils. Trends Parasitol. 2009;25(4):145–7.PubMedCrossRef Jochim RC, Teixeira C. Leishmania commandeers the host inflammatory response through neutrohils. Trends Parasitol. 2009;25(4):145–7.PubMedCrossRef
6.
go back to reference Alvar J, Aparicio P, Aseffa A, Boer MD, Cañavate C, Jean-Pierre Dedet, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21(2):334–59.PubMedCrossRef Alvar J, Aparicio P, Aseffa A, Boer MD, Cañavate C, Jean-Pierre Dedet, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21(2):334–59.PubMedCrossRef
7.
go back to reference Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis. 2009;48(2):e16–22.PubMedCrossRef Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis. 2009;48(2):e16–22.PubMedCrossRef
8.
go back to reference Seifert K, Perez-Victoria FJ, Stettler M, Sanchez-Canete MP, Castanys S, Gamarro F, et al. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistant that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents. 2007;30(3):229–35.PubMedCrossRef Seifert K, Perez-Victoria FJ, Stettler M, Sanchez-Canete MP, Castanys S, Gamarro F, et al. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistant that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents. 2007;30(3):229–35.PubMedCrossRef
9.
go back to reference Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, et al. Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg. 2010;105(2):115–7.PubMedCrossRef Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, et al. Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg. 2010;105(2):115–7.PubMedCrossRef
10.
go back to reference Sundar S, Sinha PK, Rai M, Verma DK, Kumar N, Alam S, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011;377(9764):477–86.PubMedCrossRef Sundar S, Sinha PK, Rai M, Verma DK, Kumar N, Alam S, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011;377(9764):477–86.PubMedCrossRef
Metadata
Title
A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy
Authors
Nawin Kumar
Prabhat Kumar Sinha
Krishna Pandey
Neena Verma
Chandra Shekhar Lal
Alok Ranjan
Rakesh Bihari Verma
Pradeep Das
Publication date
01-10-2011
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 5/2011
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-011-9544-8

Other articles of this Issue 5/2011

International Journal of Clinical Pharmacy 5/2011 Go to the issue